As a European preclinical cardiovascular contract research organization (CRO), InnoSer offers you a portfolio of gold-standard mouse models of common cardiovascular diseases and heart failure (with models of both HFrEF and HFpEF). By leveraging our expertise in cardiovascular disease modeling together with our specialized facilities and trained personnel equipped for reliable execution of technical cardiac surgeries and other technical imaging and functional procedures, InnoSer ensures you obtain robust data while ensuring flexible study start-up times.  

Choosing InnoSer as your cardiovascular CRO services research partner allows you to combine both disease model expertise with pharmacology, providing valuable insight into mechanism of action (MoA), pharmacokinetics/ pharmacodynamics (PK/PD profiling) and early-stage toxicity of your lead compounds. InnoSer’s cardiovascular study experts possess relevant experience in working with multiple therapy types ranging from small molecules, biologics to (stem) cell therapy approaches for multiple cardiovascular indications. InnoSer’s study expert team works with you to confidently demonstrate the safety and efficacy profile of your novel investigational compound.